Schedule-dependent effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus (RAD001)

被引：0
|
作者：
Di Cosimo, S
Matar, P
Rojo, F
Guzman, M
Rodriguez, S
Jimenez, J
Arribas, J
Cognetti, F
Lane, H
Baselga, J
机构：
[1] Vall Hebron Univ Hosp, Barcelona, Spain
[2] Regina Elena Inst Canc Res, I-00161 Rome, Italy
[3] Novartis Pharma AG, Basel, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3074
引用
收藏
页码：213S / 213S
页数：1
相关论文
共 50 条
  • [1] SEQUENCE-DEPENDENT EFFECT OF COMBINED PI3K/AKT/MTOR TARGETING WITH THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR GEFITINIB AND THE MAMMALIAN TARGET OF RAPAMYCIN (MTOR) INHIBITOR EVEROLIMUS
    Di Cosimo, Serena
    Matar, Pablo
    Rojo, Federico
    Guzman, Marta
    Rodriguez, Sonia
    Jimenez, Jose
    Martinelli, Erika
    Arribas, Joaquin
    Lane, Heidi
    Cognetti, Francesco
    Baselga, Jose
    ANNALS OF ONCOLOGY, 2004, 15 : 37 - 37
  • [2] Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells
    Eva Juengel
    Johanna Engler
    Iyad Natsheh
    Jon Jones
    Ausra Mickuckyte
    Lukasz Hudak
    Dietger Jonas
    Roman A Blaheta
    BMC Cancer, 9
  • [3] Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells
    Juengel, Eva
    Engler, Johanna
    Natsheh, Iyad
    Jones, Jon
    Mickuckyte, Ausra
    Hudak, Lukasz
    Jonas, Dietger
    Blaheta, Roman A.
    BMC CANCER, 2009, 9
  • [4] The mTOR (mammalian target of rapamycin) inhibitor RAD001 (Everolimus) is safe and reduces proliferation in postmenopausal women with breast cancer
    Macaskill, E. J.
    Bartlett, J. M. S.
    Renshaw, L.
    Faratian, D.
    White, S.
    Campbell, F. M.
    Young, O.
    Stumm, M.
    Thomas, J.
    Barber, M. D.
    Dixon, J. M.
    EJC SUPPLEMENTS, 2007, 5 (03): : 30 - 30
  • [5] Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis
    Parikh, Sameer A.
    Kantarjian, Hagop M.
    Richie, Mary Ann
    Cortes, Jorge E.
    Verstovsek, Srdan
    LEUKEMIA & LYMPHOMA, 2010, 51 (02) : 269 - 274
  • [6] Combination of rituximab and mammalian target of rapamycin inhibitor everolimus (RAD001) in diffuse large B-cell lymphoma
    Xu, Zi-Zhen
    Wang, Wen-Fang
    Fu, Wan-Bin
    Wang, Ai-Hua
    Liu, Zhi-Yin
    Chen, Li-Yun
    Guo, Pei
    Li, Jun-Min
    LEUKEMIA & LYMPHOMA, 2014, 55 (05) : 1151 - 1157
  • [7] Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer
    Manegold, Philipp C.
    Paringer, Carmen
    Kulka, Ulrike
    Krimmel, Klaus
    Eichhorn, Martin E.
    Wilkowski, Ralf
    Jauch, Karl-Walter
    Guba, Markus
    Bruns, Christiane J.
    CLINICAL CANCER RESEARCH, 2008, 14 (03) : 892 - 900
  • [8] mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor
    Lane, Heidi A.
    Wood, Jeanette M.
    McSheehy, Paul M. J.
    Allegrini, Peter R.
    Boulay, Anne
    Brueggen, Joseph
    Littlewood-Evans, Amanda
    Maira, Sauveur-Michel
    Martiny-Baron, Georg
    Schnell, Christian R.
    Sini, Patrizia
    O'Reilly, Terence
    CLINICAL CANCER RESEARCH, 2009, 15 (05) : 1612 - 1622
  • [9] A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC)
    Slomovitz, B. M.
    Lu, K. H.
    Johnston, T.
    Munsell, M.
    Ramondetta, L. M.
    Broaddus, R. R.
    Coleman, R. L.
    Walker, C.
    Gershenson, D. M.
    Burke, T. W.
    Wolf, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL
    Thomas Decker
    Michael Sandherr
    Katharina Goetze
    Madlen Oelsner
    Ingo Ringshausen
    Christian Peschel
    Annals of Hematology, 2009, 88 : 221 - 227
12345